AZD-5305
- Generic Name
- AZD-5305
Pipeline Analysis Reveals 85+ Drugs in Development for Metastatic Prostate Cancer Treatment
• DelveInsight's comprehensive analysis identifies over 80 pharmaceutical companies actively developing 85+ pipeline drugs for metastatic prostate cancer treatment.
• Novel therapies in development include TAVT-45, a reformulated abiraterone acetate, and Onvansertib, a first-in-class PLK1 inhibitor, demonstrating innovation in treatment approaches.
• Multiple clinical trials are underway, including Phase III studies by major players like Bayer, AstraZeneca, and Novartis, evaluating new treatment combinations and targeted therapies.
Bayer's Elinzanetant Shows Promise in Reducing Hot Flashes for Breast Cancer Patients
• Elinzanetant met primary endpoints in the Phase III OASIS 4 trial, significantly reducing the frequency of moderate to severe vasomotor symptoms (VMS) in women undergoing endocrine therapy for breast cancer.
• The study also achieved secondary endpoints, demonstrating a reduction in the severity of VMS, improvements in sleep disturbances, and enhanced menopause-related quality of life compared to placebo.
• Elinzanetant is a dual neurokinin-1 and 3 receptor antagonist, representing a potential non-hormonal treatment option for VMS in breast cancer patients and women at high risk.
• Bayer is advancing regulatory submissions for elinzanetant in the US, EU, and other global markets, with potential launch expected later this year, pending regulatory approvals.
Enhertu Approved for HER2-Low and HER2-Ultralow Metastatic Breast Cancer
• The FDA has approved Enhertu for HR-positive, HER2-low or HER2-ultralow metastatic breast cancer after endocrine therapy progression.
• DESTINY-Breast06 trial data showed a 36% reduction in disease progression or death risk compared to chemotherapy.
• Patients on Enhertu had a median progression-free survival of 13.2 months versus 8.1 months on chemotherapy.
• This approval expands Enhertu's use to an earlier treatment setting and a broader patient population.
PETRA Trial Shows Promise in Metastatic Breast Cancer with Novel Drug Combination
• A patient with metastatic triple-negative breast cancer experienced a 65% reduction in tumor size through the PETRA clinical trial.
• The trial utilizes a combination of AZD5305, a PARP inhibitor, and Trastuzumab Deruxtecan (T-Dxd) to target cancer cells.
• The PETRA trial is investigating the safety and efficacy of AZD5305 in combination with other treatments across various advanced solid tumors.
• This approach offers renewed hope for patients with aggressive breast cancer who have limited treatment options.
Next-generation PARP Inhibitor Shows Promise in Treating HRR-Deficient Breast Cancer
Saruparib, a selective PARP1 inhibitor, has demonstrated significant clinical benefits in patients with homologous recombination repair (HRR)-deficient breast cancer, showing a promising objective response rate and progression-free survival. The drug's higher selectivity for PARP1 improves safety and tolerability, allowing for higher doses and potentially better efficacy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath